
Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

Curevac NV sues BioNtech for IP infringement
On Monday, CureVac filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE and two of its subsidiaries, seeking compensation...

Evotec signs contracts with Almirall and Sernova
Under the alliance Evotec is set to discover novel targets or therapeutics for skin diseases such as atopic dermatitis or basal cell carcinoma....

Study shows advantages of cellular agriculture
Replacing animal-source foods (ASFs) with novel or future foods (NFFs) – such as cultured milk, insect meal or mycoprotein – or plant-based...

Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
Swiss Urovant Science, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., will receive up to USD $75m in upfront payment, regulatory, and sales...

Four new autoantigens trigger multiple sclerosis
Despite considerable progress in the treatment of multiplesclerosis (MS), the disease still often leads to permanent neurological disability....

Switzerland shows sustained growth of biotech sector
Capital investments in Swiss biotech companies reached the second-best amount ever with CHF3.33bn in the second year of the pandemic, according to...